Denali Therapeutics (DNLI) Other Non-Current Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Other Non-Current Assets data on file, last reported at $26.2 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 2.65% year-over-year to $26.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.2 million (down 2.65% YoY) and the FY2025 annual result came in at $25.9 million, up 4.84% from the prior year.
• Other Non-Current Assets advanced to $26.2 million in Q1 2026 per DNLI's latest filing, from $25.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $50.6 million in Q2 2024 and bottomed at $11.1 million in Q3 2023.
• The 5-year median for Other Non-Current Assets is $23.0 million (2025), against an average of $23.0 million.
• The widest annual swing landed in 2022, when Other Non-Current Assets soared 326.71%; it then slumped 54.58% in 2025.
• Tracing DNLI's Other Non-Current Assets over 5 years: stood at $13.4 million in 2022, then soared by 35.41% to $18.1 million in 2023, then surged by 36.37% to $24.7 million in 2024, then advanced by 4.84% to $25.9 million in 2025, then gained by 1.08% to $26.2 million in 2026.
• Per Business Quant, the three latest DNLI Other Non-Current Assets figures stand at $26.2 million (Q1 2026), $25.9 million (Q4 2025), and $25.1 million (Q3 2025).

Peer Comparison